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207METHODS: We conducted a multicenter, observational study in Italian patients with hyperLp(a) and
premature CAD with (n 5 18)/without (n 5 16) LA in which blood samples were analyzed for Lp(a)
parameter and CLS. Genetic profiling of LPA was conducted in patient receiving LA.
RESULTS: Mean macrophage CLC of the pre-LA serum was significantly higher than that of nor-
molipidemic controls (19.7 6 0.9 mg/mg vs 16.01 6 0.98 mg/mg of protein, respectively). After LA,
serum macrophage CLC was markedly lower relative to preapheresis (16.1 6 0.8 mg/mg protein;
P 5 .003) and comparable with CLC of the normolipidemic serum. LA did not significantly affect
average apo(a) isoform size distribution. No anthropometric or lipid parameters studied were related
to serum CLC, but there was a relationship between CLC and the Lp(a) plasma concentration
(P 5 .035). DNA analysis revealed a range of common genetic variants. Two rare, new variants
were identified: LPA exon 21, c.3268C.G, p.Pro1090Arg, and rs41259144 p.Arg990Gln, c.2969G.A
CONCLUSIONS: LA reduces serum Lp(a) and also reduces macrophage CLC. Novel genetic vari-
ants of the LPA gene were identified, and geographic variations were noted. The complexity of these
polymorphisms means that genetic assessment is not a predictor of CAD risk in hyperLp(a).
















































Several studies, including meta-analyses, have reported
that risk of coronary artery disease (CAD) is increased as
plasma lipoprotein(a) (Lp(a)) concentration increases.1–3
Various studies have been conducted on the association be-
tween small apo(a) isoform size and increased CAD risk,4
showing that not only is small size associated with high
Lp(a) concentration5 but also that the size predicts CAD
with greater strength and independence than Lp(a) concen-
tration.6 In patients with high levels of Lp(a) and progres-
sive CAD, lipoprotein apheresis (LA) is at present the
only effective therapeutic option.3
Cholesterol loading capacity (CLC) is a cellular param-
eter used for the evaluation of the proatherogenic capacity
of the serum to load cells with cholesterol. CLC informs on
both the free cholesterol and multigenic lipoprotein influx7
and on the efflux capacity of lipoprotein in circulating mac-
rophages.8 Increases in CLC contribute to the development
of foamy infiltrate and is therefore considered to be a proa-
therogenic cellular index. CLC appears to be increased in
cardiovascular disease and is associated with increased car-
diovascular risk.9,10
The gene coding for Lp(a) is the LPA gene localized on
chromosome 6q27 and is characterized by high sequence
homology (78%–100%) to human plasminogen in the
untranslated and coding regions.11 A characteristic feature
of apo(a) is the presence of loop-like structures called krin-
gles. Kringle domains are triple-loop structures stabilized
by 3 internal disulfide bonds. The kringle IV (KIV) domain
in Lp(a) results in ten different types of KIV domains, all
unique in their amino acid composition. Among the KIV
encoding domains, KIV-1 and KIV-3 to KIV-10 are present
only as single copies. The kringle IV type 2 (KIV-2)
domain is further expanded resulting in a multiallelic, intra-
genic copy number variation (from 1 to 40 repeat se-
quences) known as the KIV-2 copy number variation
polymorphism.11 This polymorphism is the most important
predictor of variations in Lp(a) concentration in the range
40%–70%.12FLA 5.6.0 DTD  JACL1577_prooConsidering single-nucleotide LPA polymorphisms, 2
genetic variants—rs3798220 (a nonsynonymous single-
nucleotide polymorphisms [SNPs] in the protease domain)
and rs10455872 (an intronic SNP)—have been found to be
associated with particularly high levels of Lp(a), and both
are associated with an elevated cardiovascular risk.13 Step-
wise regression identified 7 SNPs that each had a signifi-
cant association with Lp(a) levels and together explained
40% of the total variation. Genome-wide studies and subse-
quent meta-analysis confirmed the strongest association be-
tween CAD and rs10455872 and rs3798220
polymorphisms.14,15
Lp(a) levels are increased in familial hypercholesterole-
mia (FH)16 and in familial defective apolipoprotein B-
100.17 Only recently, 2 additional genes were found to be
implicated into Lp(a) metabolism: APOE and PCSK9.
The isoform APOE2 is associated with 15% lower Lp(a)
concentrations, whereas the Lp(a)-increasing effect of
APOE4 is controversial and vanishes after apo(a) isoform
adjustment.15 In line with the effects of proprotein conver-
tase subtilisin/kexin type 9 (PCSK9) inhibitors, the PCSK9
LOF mutation R46L (rs11591147) decreases Lp(a) levels.18
In the present study, we evaluated the relationship
between Lp(a) and CLC, as an index of cellular proather-
ogenicity of the serum, by determining Lp(a) concentration
and apo(a) size in patients with a high level of serum Lp(a)
and CAD. We also examined how LA influences the
concentration and the size of Lp(a) particles and the serum
CLC levels in these patients. Genetic sequencing for LPA
polymorphisms was conducted on a case series of patients
with elevated Lp(a). The number of cases studied is relatively
small. However, it is to be considered that complex and in-
depth laboratory evaluations were carried out.
Subject and methods
Subjects and study design
This was a multicenter, observational study in patients
with hyperLp(a) (isolated and combined forms) and pre-
mature CAD. The study included 34 patients (mean agef  7 June 2020  1:13 am
13


































































































































38559.5 6 8.9 years, men 70%) collected from 3 Italian
hospitals (Roma 24 of 34, Verona 9 of 34, Pistoia 1 of 34).
All patients were on maximally tolerated lipid-lowering
therapy: 14 patients were treated with statins, 16 with
statins plus ezetimibe, one patient with alirocumab, and one
patient with lomitapide. Eighteen patients were chronically
treated with LA (LA group), whereas 16 patients with
hyperLp(a) and CAD never submitted to LA and were used
as the control group.
Ethics
MightyMedic.org projects are conducted in accordance
with the Declaration of Helsinki and International Confer-
ence on Harmonization Good Clinical Practice guidelines.
Where required, approval has been obtained from the
institutional review board at each participating center. Writ-
ten informed consent is received from all enrolled patients.
Lipoprotein apheresis
Selective LA procedures were conducted weekly or
every 2 weeks (Q2W) using one of the 3 most common
techniques: heparin-induced LDL precipitation apheresis
(HELP, Plasmat Futura; B. Braun, Melsungen, Germany;
11 of 18 patients), dextran sulfate absorption from plasma
(Liposorber-LA systems; Kaneka, Osaka, Japan; 4 of 18
patients), or direct adsorption of lipoproteins (Fresenius
Medical Care DALI 1000/1250; 3 of 18 patients).
Blood sampling was conducted before and immediately
after one LA session to evaluate plasma lipids, apo(a)
concentration, and average apo(a) isoform size, and to
determine CLC. Total cholesterol, HDL cholesterol, and
triglycerides were measured by standard enzymatic tech-
niques. Lp(a) levels were determined by nephelometry.
LDL cholesterol (LDL-C) was calculated as per the
Friedewald formula.
Apo(a) isoform size estimation
Chemicals
Ammonium bicarbonate (ABC), dithiothreitol, iodoa-
cetamide, sodium deoxycholate (DOC), and formic acid
were supplied by Sigma-Aldrich Srl (Milan, Italy). Mass
Spectrometry Grade Trypsin Gold (code number: V5280)
was supplied by Promega Srl (Promega, Milan, Italy).
Proteotypic peptide LFLEPTQADIALLK used for deter-
mining apo(a) concentration and GTYSTTVTGR used
for identification of KIV-2 repeating sequence, together
with the corresponding 13C15 N-labeled standards, were
obtained from New England Peptides (Gardner, MA)—
purity of these was .95% according to high-
performance liquid chromatography (HPLC) analysis by
the manufacturer. Recombinant apo(a) isoform calibra-
tors for apo(a) size attribution containing 10, 14, and
18 kringles, respectively, were provided by Prof. Eduardo
Angles-Cano.FLA 5.6.0 DTD  JACL1577_proTryptic digestion of human serum samples
For the digestion of human serum samples, the protocol
published by Lassman et al19 was used with minor modifi-
cations. Briefly, 4 mL of plasma of each patient was diluted
with 132 mL of 50 mM ABC, pH 8.0, 10 mL of a 10% w/v
DOC solution, and 50 mL of a 100 nM solution of labeled
internal standards in ABC, to reach a final volume of
200 mL. The samples were then subjected to a standard
reduction/alkylation/digestion protocol using 2 mL of a
500 mM solution of dithiothreitol for 30 min at 60C, fol-
lowed by 2 mL of a 1 M solution of iodoacetamide for 1 h at
room temperature in the dark. Trypsin digestion occurred
overnight using 3 mg of trypsin per sample, as already
described. Ten microliter of a 20% v/v formic acid solution
was added to stop digestion and to precipitate the DOC.
The samples were centrifuged (15 min, 3000 g, 4C), and
10 mL of the acid supernatant was directly injected into
the HPLC-MS/MS system for analysis.
Tryptic digestion of recombinant apo(a)
isoforms
The 3 recombinant apo(a) isoforms used as calibrators
were supplied as stock solutions in culture medium (com-
plete RPMI medium 1 10% fetal calf serum) harvested
from a CELLine bioreactor. They were received in dry ice,
split into aliquots, and stored at 270C until use. Their
concentration had been previously measured using IED
assay rocket electrophoresis and was equal to 0.948 mg/mL
for the 10 kringles apo(a), 0.339 mg/mL for the 14 kringles
apo(a), and 0.675 mg/mL for the 18 kringles apo(a). The
stock solutions of recombinant apo(a) were serially diluted
and digested overnight with trypsin in the presence of 4 mL
of human serum, which, having been previously digested
following the same protocol described previously, had no
detectable levels of the corresponding proteotypic peptides.
High-performance liquid chromatography
coupled to mass spectrometry (HPLC-MS/MS)
analytical method
The digested samples were analyzed on a Thermo
Accela UHPLC system coupled to a Thermo TSQ Quantum
Access Max triple quadrupole mass spectrometer (Thermo,
Milan, Italy) equipped with a heated electrospray ionization
(H-ESI Q) ion source. The separation occurred by gradient
elution; eluent A: acetonitrile 1 0.1% formic acid; eluent
B: water 1 0.1% formic acid. Time: t 5 0 minute: 2%A;
98%B; t 5 5 minute: 2%A; 98%B; t 5 20 minute: 30%
A; 70%B; t 5 22 minute: 95%A; 5%B; t 5 23 minute:
95%A; 5%B; and t 5 24 minute: 2%A; 98%B followed
by 4-minute re-equilibration time. Total run time: 28 min-
ute. The HPLC column was a Phenomenex Synergi Fusion
C18 (150 ! 2.1 mm, 3 mm particle size) with a flow rate of
350 mL/min. Injected volume was 10 mL. The mass spec-
trometer acquired data in electrospray positive ionizationof  7 June 2020  1:13 am
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515(ESI1) and multiple reaction monitoring mode. ESI of pep-
tides of interest was optimized by flow injection analysis of
a 10 mM solution in 50% water containing 0.1% HCOOH:
50% MeOH. The following parent–product ion transitions
were applied: GTYSTTVTGR [M12H]21 m/
z 5 521.8/721.4; 634.5; 136.0 (tube lens (TL) 5 74V;
collision energy (CE) 5 19; 20; 27 eV); internal standard
GTYSTTVTGR[13C6
15N4] [M12H]
21 m/z 5 526.8
/731.4; 543.2; 135.9 (TL 5 75 V; CE 5 19; 20;
28 eV); LFLEPTQADIALLK [M12H]21 m/
z 5 786.5/1070.0; 260.8; 232.9 (TL 5 101 V;
CE 5 27; 31; 38 eV); internal standard LFLEPTQA-
DIALLK[13C615N2] [M12H]21 m/z 5 790.5/1078.0;
260.8; 232.8 (TL 5 101 V; CE 5 26; 30; 36 eV). HPLC-
MS/MS data were acquired and processed by Thermo Xca-
libur software (version 1.3). GraphPad Prism (GraphPad
Software Inc, version 6.01) was used for data analysis
and graphs.
Cholesterol loading capacity
Measurement of intracellular cholesterol was conducted
via enzymatic determination on cell extracts as already
described.9 Human macrophages derived from THP-1 were
used as a model to evaluate the accumulation of intracel-
lular cholesterol induced by exposure to patient sera.
THP-1 monocytes were plated in 24-well plates in RPMI
at 10% of fetal calf serum in a number of 500,000 cells per
well and treated with PMA at a concentration 100 ng/mL to
induce macrophage differentiation and substrate adhesion.
After 72 hours, after a wash with PBS, the incubation of
the cells began with 5% of patient’s sera and the control
sera for 8 hours; the negative control consists of cells incu-
bated with only the medium. The cells were then lysed to
dose the cholesterol and the protein content.
The macrophages were lysed with a 24-hour incubation
at room temperature in 250 mL of 1% cholic acid solution
and DNA-ase 50 U/mL. Each well was filled with 62.5 mL
of a reaction buffer containing 0.5% triton-X-100, potas-
sium phosphate 0.5 M (pH5 7.4), and 1% sodium cast, left
to incubate for 30 min. The lysis of the cell monolayers was
completed with repeated aspirations and extrusions through
a 1 mL thin needle syringe. Aliquots (300 mL) were
transferred from each well to plastic tubes then sonicated
for 30 minutes. The samples were incubated at 60C in a
thermostatic bath to inactivate any enzymes interfering with
the cholesterol quantification reaction. The standard choles-
terol scale was prepared in duplicate in 96-well plates by
adding 0, 2, 5, 10, 20, and 30 mL of 0.1 mg/mL cholesterol to
the wells and resulting in a final volume of 50 mL with the
reaction buffer contained in the Amplex Red Cholesterol
Assay Kit (Molecular Probes, Life Technologies). A 50-mL
aliquot of each cell extract was then added to each well. At
the end, 50 mL of Amplex Red reagent was added to each
sample and standards. A fluorimeter reading was taken with
excitation wavelength at 535 nm and emission at 585 nm.
The results obtained were expressed in relation to theFLA 5.6.0 DTD  JACL1577_prooprotein content of each extract. The protein content in each
extract was measured by the bicinchoninic acid method.
96-well plates were used to plate-out the standard protein
scale (0, 3.125, 6, 12, 5, 25, 50, and 100 mg of albumin).
The scale was prepared in duplicate using a 4 mg/mL
albumin stock and taking 1: 2 serial dilutions starting from
100 mg up to 3.125 mg. Standards were made up to the
volume with the sample lysis buffer. All samples (25 mL;
standard scale and cell extracts) were mixed with 200 mL of
a mixture of A and B solutions from the kit in a 50:1 ratio,
with an incubation of 20 minutes at room temperature.
Solution A consisted of 20 g of sodium carbonate, 4 g of
soda, and 0.2 g of sodium tartrate (or 0.237 g of sodium
hydrochloride tartrate) in 1 L of deionized water; solution B
is instead composed of 5 g of copper sulfate in 1 L of
deionized water. The developed color was measured at the
spectrophotometer with a 550 nm filter. Protein concentra-
tion was calculated based on the standard albumin curve,
and the total protein content per well was taken against the
dilution volume.
Statistical analysis
The results were expressed as mean6 SEM. Differences
in 7 variables associated with the lipid profile before and
after LA were evaluated by means of a paired t-test.
Because the analysis concerned multiple comparisons, the
Bonferroni correction was applied, which sets the statistical
cutoff for each comparison to a/n set at 0.007.
Two nested linear regression models were estimated to
check for the effects of a set of variables on the levels of the
CLC. The first model involves 2 demographic variables
(age and gender), the BMI, the smoking attitude of the
patient, the concentrations of LDL, Lp(a), and triglycerides
as explanatory variables. Gender and smoking attitude are
categorical variables, whose reference categories are men
and nonsmokers, respectively. The second model adds the
variable concerning the Lp(a) size (Kn). The improvement
in model fit between the 2 nested models was tested and
assessed by performing an F test of statistical significance
on the change in R2.
On account of the small size of the sample, the
regression models described previously were estimated
using a limited number of variables. Therefore, total
cholesterol was excluded because of collinearity problems
with other cholesterol variables such as triglycerides and
LDL, whereas HDL was excluded because it had little
biological relevance to accumulation of intracellular
cholesterol.
Gene sequencing
Next-generation sequencing based on a custom Ampli-
Seq panel designed for sequencing of human genes related
to the lipoprotein metabolism (including LPA, PCSK9,
APOE, and LDLR) was performed with Ion PGM
Sequencer (Fig. 1). The genomic DNA from venous bloodf  7 June 2020  1:13 am
Q15
Figure 1 Correlation between MS- and Ab-based apo(a) and
Lp(a) serum quantification. Ab, antibody; Lp(a), lipoprotein(a);
MS, mass spectrometry.















































































































626samples was extracted from 200 mL blood applying the
blood and body fluid spin protocol provided in the QIAamp
DNA Blood Mini Kit (Qiagen, Milan, Italy). A multiplex
PCR amplification strategy for the coding DNA sequences
was accomplished online (Ion AmpliSeq Designer; http://
www.ampliseq.com) to amplify the target region with 25
base pair exon padding. About 20 ng DNA per sample
was used for the target enrichment by a multiplex PCR,
and each DNA pool was amplified with the Ion AmpliSeq
Library Kit in conjunction with the Ion AmpliSeq ‘‘Custom
Primer Pool.’’ Protocols were conducted as per the manu-
facturer’s procedures (Life Technologies, Darmstadt, Ger-
many) using the Ion Chef System. Enriched ISPs, which
carried many copies of the same DNA fragment, were sub-
jected to sequencing on an Ion 316 Chip to sequence pooled
libraries with 12 samples. The 316 chip was chosen to
obtain a mean sequencing depth of coverage of 50! which
means that, on average, each base had been sequenced
50! when eleven samples were loaded. Sequencing was
performed using a sequencing kit (Ion PGM reagents;
Life Technologies, Monza (MI), Italy). The raw data (un-
mapped BAM-files) from the sequencing runs were pro-
cessed using Torrent Suite software (Version 4.4.2, Life





CAD (#vessels involved) (mono-/bi-/trivasal) N 4
Carotid (stenosis,69%/CAS or CEA) N 3
Cigarette smoking (previous/never/current) N 1
Lipid-lowering therapy (statins/statins 1 ezetimibe/
PCSK9i/lomitapide) N
5
CAD, coronary artery disease; CAS, carotid angioplasty and stenting; CEA
treatment.
FLA 5.6.0 DTD  JACL1577_proalignments, which are filtered by the software into mapped
BAM files using the reference genomic sequence (hg19-
human genome 19) of target genes. Variant calling was per-
formed with the Torrent Variant Caller Plugin using as key
parameters: minimum allele frequency 5 0.015, minimum
quality 5 10, minimum coverage 5 20, and minimum
coverage on either strand5 3. The annotation of called var-
iants was performed using the Ion Reporter software
(Version 4.4; Life Technologies, Monza (MI), Italy) for
the VCF files that contained the nucleotide reads.
All new missense variants were analyzed with in silico
software PolyPhen and SIFT, predicting the effect of
mutation on the function of a protein. These 2 tools predict
the effect resulting in an amino acid substitution on the
structure and function of a protein.Results
Subjects
Demographic, disease, and treatment parameters are
shown in Table 1. The baseline lipid parameters and CLC
are shown in Table 2. Age, BMI, lipid-lowering therapy, ca-
rotid artery disease, smoking habit, and baseline lipid pro-
file were similar in the 2 groups, whereas in the LA-group,
CAD was more severe and CLC was higher (19.6 6 3.7 vs
15.7 6 3.5 mg/mg of protein, P 5 .004) than in the control
group. The 18 patients in the LA group were on chronic LA
for a median period of 5 years (range 1–27 years).
Comparison of MS-based and Ab-based methods
for determination of serum levels of Lp(a)
We used an HPLC-MS/MS method to analyze human
serum samples (n 5 52) of the MM multicentric study. The
area ratio of the LFLE peptide and its labeled internal
standard LFLE* were correlated to the Lp(a) levels,
expressed in mg/dL unit, which had been measured
by conventional antibody-based (Ab-based)logical treatment Q2
LT 1 LA (N 5 18) LLT (N 5 16) P*
/16 8/8
0 6 10 59 6 8 ns





, carotid endarterectomy; LA, lipoprotein apheresis; LLT, lipid-lowering





















Table 2 Baseline lipids, lipoproteins, and cholesterol loading capacity
Parameter, mean 6 SD LLT 1 LA (N 5 18) LLT (N 5 16) P*
Total cholesterol (mg/dL) 171 6 39 180 6 39 ns
LDL cholesterol (mg/dL) 97 6 34 106 6 34 ns
HDL cholesterol (mg/dL) 50 6 10 50 6 8 ns
Triglycerides (mg/dL) 123 6 56 121 6 34 ns
Lp(a) mg/dL; median 117 115 ns
[range i.q.] [94.3-135.0] [99.2-137.7]
CLC ug/mg of protein 19.7 6 3.7 16.1 6 3.57 .009
CLC, cholesterol loading capacity; LLT, lipid-lowering treatment; LA, lipoprotein apheresis; Lp(a), lipoprotein(a).












































































































753immunoturbidimetric methods.20 A Spearman nonpara-
metric correlation rho of 0.8315 was obtained, suggesting
a positive monotonic correlation among the 2 variables
(P , .0001) (Fig. 1).
Average size of apo(a)
The tryptic digestion of 3 recombinantly expressed
apo(a) isoforms containing a different KIV-2 copy number
(K10; K14; and K18) was used to relate the GTYS/LFLE
peptide area ratios to the average size of apo(a) in unknown
patient samples (Materials and Methods). As it can be seen
from data in Supplementary Table 1, the GTYS/LFLE pep-
tide area ratio remained constant as the concentration of
each trypsin-digested recombinant apo(a) increased but
proportionally increased among the different recombinant
apo(a)s as a function of the KIV-2 number copies. Thus,
the equation GYTS/LFLE ratio 5 0.569 (60.002) KIV-2
- 4.702 (60.010); r2 5 0.999; s 5 0.10; F 5 132,300;
n 5 3, was used to calculate the average KIV-2 copy num-
ber (ie, average apo(a) size) in the undetermined patient
samples. Then, the derived apo(a) average size was related
to in vitro CLC and was used to evaluate the effect of LA




TC (mg/dL) 171.2 6 9.2
TG (mg/dL) 123.4 6 13.1
LDL-C (mg/dL) 97.6 6 7.9
HDL-C (mg/dL) 49.7 6 2.3
Lp(a) (mg/dL) 131.6 6 17.9




CLC, cholesterol loading capacity; TC, total cholesterol; TG, triglyceride; L
Lp(a), lipoprotein (a).
Values are expressed as mean 6 SEM (n 5 18). Variables in bold are s
comparisons.
FLA 5.6.0 DTD  JACL1577_proo
754Effect of lipoprotein apheresis on plasma lipids
Data on circulating lipid levels before and after LA are
shown in Table 3. As expected, levels of TC, TG, LDL-C,
and Lp(a) markedly reduced immediately after LA
[251,64% (P 5 .00001), 252,03% (P 5 .00001),
269,67% (P 5 .00001), and 265,43% (P 5 .00001),
respectively]. HDL cholesterol was also reduced by LA
[215,69% (P 5 .0003)]. The HPLC-MS/MS method was
also used to evaluate the efficiency of the LA treatment
in decreasing the plasma concentration of Lp(a), by evalu-
ating the percentage decrease in the LFLE/LFLE* peptide
area ratios in preapheresis and postapheresis samples
(Fig. 2). The mean percentage decrease was
66.2 6 11.7% and not significantly different from values
obtained by the Ab-based method (65.0 6 11.7%). Only
for n 5 4 patients, the difference between the percentage
decrease provided by the 2 methods was .15%.
Patient serum macrophage CLC before and after
lipoprotein apheresis
Serum macrophage CLC was evaluated using patient
sera obtained before and after LA to deliver cholesterol totein apheresis
After lipoprotein
apheresis t P-value
82.8 6 4.7 11.452 ,.001
59.2 6 9.8 8.116 ,.001
29.6 6 3.0 9.478 ,.001
41.9 6 2.0 3.677 ,.001
45.5 6 6.3 6.639 ,.001
16.1 6 0.8 3.139 .003
18.1 6 0.5 2.646 .009
DL-C, LDL cholesterol; HDL-C, HDL cholesterol; KIV-2, kringle IV type 2;
tatistically significant at P , .007, after Bonferroni’s correction for 7























Figure 2 Comparison of Ab- and MS-based methods in evalu-
ating the effect of LA on Lp(a) serum concentrations. Ab, anti-
body; Lp(a), lipoprotein(a); LA, lipoprotein apheresis; MS, mass
spectrometry.















































































































886human macrophages THP-1. THP-1 initial cholesterol
content before the exposure with serum was
13.90 6 0.54 mg/mg of protein. The macrophage CLC of
the pre-LA serum was significantly higher than that of the
normolipidemic serum added as a control (mean 6 SD
19.7 6 0.9 mg/mg of protein and 16.01 6 0.98 mg/mg of
protein, respectively). After LA, serum macrophage CLC
was markedly lower relative to preapheresis sera
(mean6 SD 16.16 0.8 mg/mg protein; P5 .003) and com-
parable with CLC of the normolipidemic serum (Table 2).
The LA did not significantly affect average apo(a) isoform
size distribution, evaluated by means of the GTYS/LFLE
peptide area ratios and back-calculated KIV-2 copy number
(Fig. 3).
Serum CLC and Lp(a) concentration and size
Preliminary univariate analyses of the relationship be-
tween CLC and Lp(a) (Fig. 4) have shown a poor positive
association with concentration (rho 5 0.094, P 5 .596) and
a moderate/high negative association with size
(rho 5 20.637,P , .001).
Once controlled for various potential confounding
factors in a multiple linear regression (Table 4), in modelFigure 3 Effect of LA on apo(a) isoform distribution, assessed
by changes in the GTYS/LFLE peptide area ratio. KIV-2, kringle
IV type 2; LA, lipoprotein apheresis.



















9051, Lp(a) was significantly related to serum CLC
(P 5 .035), whereas all the other anthropometric and lipid
parameters studied were not. However, the overall model fit
is not statistically significant (F 5 2.1, P 5 .088), which
means that the linear model does not describe adequately
the experimental data. In model 2, the inclusion of Lp(a)
size (KIV-2 copy number) allows highlighting either its sig-
nificant inverse relationship with CLC (b 5 20.707,
P 5 .001) or the fading of Lp(a) statistical significance
(P 5 .412). Moreover, in this model, the overall fit is statis-
tically significant (F 5 4.3, P 5 .003), which ensures more
statistical robustness to the results. The statistical relevance
of the improvement in the model fit between the 2 models is
also supported by the F test on the change in R2 (Table 5).
Such parameter increases, in fact, by 0.321 (from 0.252 in
model 1 to 0.573 in model 2), which results in a highly sta-
tistically significant improvement (P 5 .001). The partial
R2 of Lp(a) size in model 2 is 0.429, which means that
Lp(a) size explains about 43% of the total variability of
CLC, once controlled for the other variables in the model.
DNA sequencing
In our study of 18 cases in LA therapy and 16 controls
with increased levels of Lp(a), we identified 5 of the 16
genetic variants described in PROCARDIS study:
rs3798220, rs3798221, rs10755578, rs7765781, and
rs7765803 (Fig. 6 Q). In particular, 2 cases and one control
were the heterozygous carrier of rs3798220 variant (allelic
frequency: C: 0.04, PROCARDIS allele frequency: C:
0.02). In our patients, we did not find the Lp(a)-raising
rs10455872 variant; the rs3798221 variant was identified
in 2 cases and one control; the rs10755578 intronic variant
was identified in 7 cases and 7 controls (heterozygous car-
riers). The rs7765781 intronic variant was identified in 5
cases and one control (heterozygous carrier). rs7765803
p.Leu1858Val is a missense, nonpathogenic variant on
exon 26; in our study, we identified this variant in 4 cases
and 3 controls (heterozygous carriers)—one control was
homozygous for this rare variant. We did not observe differ-
ences between Lp(a) levels or cardiovascular disease
severity in 13 patients without PROCARDIS variants in
comparison with 21 patients with one or more of these
variants.
In our study, we described one or more of the following
benign or silent variants in 26 patients: rs3124784
(p.Arg2016Cys), rs41267809 (p.Leu1961Pro),
rs41264848, and rs1801693 (p.Met1679Thr). We did not
observe any differences in Lp(a) levels between carriers of
more than 4 alleles in comparison with carriers of less than
4 alleles.
In one case (age 46 years, Lp(a) levels 138 mg/dL,
pCAD), we identified a rare heterozygous LPA gene muta-
tion on exon 21, c.3268C.G, p.Pro1090Arg predicted as
‘‘pathogenic’’ at in silico analysis (SIFT 5 0.0
PolyPhen 5 1.0). One patient (age 68 years, Lp(a) levels










Figure 4 Scatterplot of the relationship between CLC and Lp(a) concentration (on the left) and CLC and Lp(a) size (on the right). CLC,
cholesterol loading capacity; Lp(a), lipoprotein(a).












































































































1013rare variant rs41259144 p.Arg990Gln, c.2969G.A
(SIFT 5 0 PolyPhen 5 0.999). The clinical significance
of these 2 new rare variants remains uncertain: in silico pro-
grams define ‘‘pathogenic’’ an amino acid substitution
likely entails a significant change of the protein structure;
however, this alteration can also be advantageous for the
species, so the ‘‘pathogenic’’ term may be inappropriate.
Seven patients of our case series are heterozygous FH
patients and one of them was homozygous FH patient.
Seven patients were carriers of the APOE ε3ε4 genotype,
and 4 patients were carriers of the APOE ε3ε2 genotype,




Age (years) 0.013 .875
BMI (kg/cm2) 20.247 .314
Sex 23.060 .176
Nonsmoker (ref. cat. smoker) 0.304 .869
LDL-C (mg/dL) 20.017 .555
Lp(a) (mg/dL) 0.023 .035
Triglycerides (mg/dL) 0.015 .463
apo(a) size (average KIV-2 copy number)
F (7, 22) 2.1
P-value .088
R2 0.252
B, regression coefficient; CLC, cholesterol loading capacity; LDL-C, LDL cho
FLA 5.6.0 DTD  JACL1577_prooaccording to the LDLR and APOE genotype. Only one
case was a carrier of p.R46L mutation on the PCSK9 gene.Discussion
This study has demonstrated that patients with elevated
Lp(a) and with an increased risk of CAD, who underwent
LA, have elevated CLC (Table 2). We also showed that
apheresis lowered Lp(a) and CLC and that these changes
were statistically concordant. LA did not alter the apo(a)
isoform size. LA markedly reduced serum lipid levels,els Q3
Model 2
e Partial R2 b P-value Partial R2
0.001 0.007 .907 ,0.001
0.029 0.007 .980 ,0.001
0.095 22.435 .263 0.104
0.001 0.172 .892 0.001
0.024 20.013 .561 0.020
0.106 0.012 .412 0.051





lesterol; Lp(a), lipoprotein (a).




























2 Change in R2F df Df
1 2.1 7 22 .088 0.252
2 16.2 1 21 .001 0.573 0.321


































































































































1164and we demonstrated that it was possible to use HPLC-MS/
MS to determine apo(a)- and Lp(a)-related parameters,
thereby offering the possibility of a simplified, low-
volume analysis.
Lp(a) is an LDL-like particle in which the hydrophobic
apoB100 is linked via a disulfide bridge to the hydrophilic
glycoprotein, apo(a), containing on average 23% carbohy-
drate content by weight.21 There is a single apo(a) molecule
for Lp(a) particle, but at least 34 apo(a) isoforms have been
identified.22 The most important size determinant for apo(a)
isoforms is the number of structural subunits called kringles
(molecular weightw17 kDa) and specifically KIV-2, which
can range from 3 to over 40 copies. Commonly used Ab-
based diagnostic methods have been standardized to mea-
sure Lp(a) levels as mass per unit volume (ie, mg/dL).
Nevertheless, mass-based assays do not take into consider-
ation the size polymorphism and heterogeneity of Lp(a)
particles among different individuals. Using immunoassays
to measure Lp(a) levels in terms of mass rather than
molarity can also lead to size-related bias if the used anti-
bodies are directed to epitopes present in the variable
portion of Lp(a) particles. Moreover, immunoassays use
an assay calibrator of fixed size, which is often not repre-
sentative of the heterogeneity of the Lp(a) population pre-
sent. In this context, diagnostic assays based on Lp(a) or
apo(a) molarity, such as MS-based assays, could provide
a more accurate assessment of Lp(a) concentration such
as low Lp(a) concentration for the individuals with large
particles and high Lp(a) concentrations for those with small
particles.
Our results support the employment of an MS-based
approach for apo(a) serum level quantification in future
studies. This technique has already been reported for
several other serum apolipoproteins and is valid provided
the conversion of peptide area ratios to nanomolar concen-
trations of apo(a) is performed using calibration data in line
with the WHO-IFCC–certified reference material of apo(a),
SRM-2B.23,24
As previously shown by Lassman et al.,19 the tryptic
peptide LFLEPTQADIALLK (LFLE) is unique to apo(a),
in human serum proteome, following BLAST search in
the UniProtKB/SwissProt database (https://blast.ncbi.nlm.
nih.gov/Blast.cgi). This peptide is only present in the con-
stant portion of apo(a), so, after tryptic digestion, the area
of the LFLE peptide signal is expected to be proportional
to the molar concentration of apo(a), independently from
the heterogeneity of its molecular weight—its isotope
labeled internal standard LFLE*, eluting at the sameFLA 5.6.0 DTD  JACL1577_proretention time in the HPLC run, can be used to normalize
matrix effects due to coeluting serum components.
Lassmann et al.19 also provided an interesting insight
into the evaluation of apo(a) average size using HPLC-
MS/MS. The tryptic peptide GTYSTTVTGR (GTYS) was
used as a marker of the KIV-2 copy number. In principle,
the bigger is the apo(a) size, the higher is the number of
KIV-2 repeats and, relating this after tryptic digestion, the
higher the concentration of the corresponding peptide
GTYS will be with respect to the concentration of peptide
LFLE. Thus, the area ratio of peptide GTYS and its labeled
internal standard GTYS* divided by the area ratio of pep-
tide LFLE and LFLE* could function as a useful parameter
to describe the mean size of the apo(a) serum population.
The main limitation of this approach has been clearly
declared by their proponents. Briefly, if apo(a) was ex-
pressed in serum as a single isoform, this MS-based
approach could be a valid alternative to the gold standard
method for apo(a) size measurement (ie, high resolution
SDS-PAGE electrophoresis). However, as most individuals
express 2 different alleles encoding for at least 2 isoforms
of apo(a) of different size, the value retrieved by HPLC-
MS/MS after tryptic digestion has to be considered an
average size value derived from generally 2 or even more
apo(a) populations. Despite this declared limitation, the
average size determination by HPLC-MS/MS could be
used within the present study as a high-throughput method
to assess the size distribution of apo(a) isoforms in the
serum of our patient samples.
Marked reductions in levels of LDL-C and Lp(a) after
LA in our study were consistent with previous reports.9 The
good correlation between MS- and Ab-based results for
determination of Lp(a) levels confirms that the MS-based
method would be, after a proper validation, a valid high-
throughput assay to check and confirm conventional Ab-
based results in hospital settings—particularly as the sys-
tem only requires very low volumes (ie, 4 mL) of human
serum per analysis.
This is a study confirming the significance of CLC as
proatherogenic parameter, although it has never been
correlated with clinical atherosclerosis, much less validated
as a predictor independent of atherogenic lipoprotein
parameters such as LDL-C, Lp(a), and apoB. However,
despite the need for better validation of the role of CLC
assay, it is well known that cholesterol may increase the
risk of CAD via direct action on macrophage inducing
foam cell formation, leading to the development of
atherosclerotic plaque.25 It has been also reported that theof  7 June 2020  1:13 am
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1263aforementioned atherogenic evolution may also be related
to different degrees26 and feature/phenotype of in vivo dys-
lipidemia, such as in our study. Because it has been demon-
strated that proatherogenic lipoproteins directly promote
the cellular influx of cholesterol,27,28 we made the choice
to focus our attention on CLC parameter in these patients
with high Lp(a) levels and CAD, submitted or not to LA.
Moreover, the approach directed at investigating CLC,
rather than CEC, has been already reported in the
literature.29
For the first time, our data from hyperLp(a) patients with
CAD demonstrate a direct association between Lp(a) size
and its proatherogenic capacity, which can be directly
measured as CLC. In particular, we found that the greater is
the Lp(a) size, the lower is the CLC patient concentration.
On the other hand, no significant relationship was high-
lighted between CLC and Lp(a) serum concentration.
Ours is the first systematic study of nonsize poly-
morphism of the LPA gene in Italian patients in LA therapy.
Our data confirmed that the LPA gene is extremely poly-
morphic but some variants, previously described in the
literature, are recurrent or absent in relation to the
geographical origin. We identified 2 novel variants never
described before, but their clinical significance remains un-
certain. The sample size of our study is not sufficient to
explore the predictive role of each variant on cardiovascular
risk. On a case-by-case basis, observing the predictive role
of each genetic variant of LPA gene vs Lp(a) levels and car-
diovascular risk is not reliable because of the complexity of
the genetic regulation of Lp(a) levels. In our study, other
genes such as APOE, LDLR, and PCSK9 did not influence
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